Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World LEIDEN, The ...
Heerlen/Leiden, the Netherlands (September 22, 2010) - Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: ...
GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that the high-titer ...
U.S. diversified health care company Johnson & Johnson has bought an 18 percent stake in biotech firm Crucell for 302 million euros ($444 million) as part of a flu vaccine development deal, the Dutch ...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands, Oct. 6 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss ...
Pharmaceutical and health care giant Johnson & Johnson announced Tuesday the successful completion of a friendly takeover of Dutch vaccine maker Crucell, for about 1.75 billion euros ($2.37 billion). ...
Dutch biotech Crucell swung to a full-year loss, hit by a vaccine impairment charge and higher operating costs, but said on Monday Korean regulators back the resumption of production at its key Korean ...
Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an ...
AMSTERDAM, Sept 25 (Reuters) - Dutch biotech firm Crucell said on Tuesday that the discontinuation of Merck & Co's experimental HIV vaccine was not related to the use of Crucell's PER.C6 technology, ...
Crucell N.V. and GeneMax Corp have entered a license agreement for Crucell's PER.C6 cell line technology. Under the terms of the agreement, GeneMax will use Crucell's PER.C6 technology for research in ...
AMSTERDAM, April 11 (Reuters) - Dutch biotech firm Crucell will be delisted from Euronext Amsterdam after the close of trading on Monday, following its takeover by U.S. healthcare company Johnson & ...
) for 1.75 billion euros ($2.42 billion). JNJ will buy the outstanding 82.1% shares of CRXL for 24.75 euros ($34.26) per share, representing a premium of 58% over CRXL's closing price on September 16.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results